Tenofovir: Gilead applies for approval; expanded access liberalized.
Patients who cannot construct a viable antiretroviral regimen with approved drugs will now have easier access to tenofovir, a drug that is currently experimental but may be approved in about six months. Tenofovir is significant because it appears to maintain its antiretroviral activity, with resistant HIV developing relatively slowly.
Gilden
D
D
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000458:organization & administration*; D015658:HIV Infections / Q000188:drug therapy; D006297:Health Services Accessibility; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load
D019380:Anti-HIV Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine